Difference between revisions of "PARP inhibitors"

From Libre Pathology
Jump to navigation Jump to search
 
(No difference)

Latest revision as of 18:28, 10 June 2024

PARP inhibitors are a class of cancer drugs.

PARP is an abbreviation for poly-ADP ribose polymerase.

Use

  • Prostate cancer.
  • Breast cancer.
  • Ovarian cancer.

Drugs

  • Olaparib (Lynparza).[1]
  • Rucaparib (Rubraca).
  • Niraparib (Zejula).[2]

See also

References

  1. ↑ Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (December 2016). "PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting". Prz Menopauzalny 15 (4): 215–219. doi:10.5114/pm.2016.65667. PMC 5327624. PMID 28250726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/.
  2. ↑ URL: https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs/types/PARP-inhibitors. Accessed on: 2024 June 10.
Retrieved from "https://librepathology.org/w/index.php?title=PARP_inhibitors&oldid=53011"